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Background andAims. Angiotensin converting enzyme 2 (ACE2) is an important component of the renin-angiotensin system. Since
angiotensin peptides have been shown to be involved in hepatic steatosis, we aimed to evaluate the hepatic lipid profile in ACE2-
deficient (ACE2−/y) mice.Methods. Male C57BL/6 and ACE2−/y mice were analyzed at the age of 3 and 6 months for alterations in
the lipid profiles of plasma, faeces, and liver and for hepatic steatosis. Results. ACE2−/y mice showed lower body weight and white
adipose tissue at all ages investigated. Moreover, these mice had lower levels of cholesterol, triglycerides, and nonesterified fatty
acids in plasma. Strikingly, ACE2−/y mice showed high deposition of lipids in the liver. Expression of CD36, a protein involved
in the uptake of triglycerides in liver, was increased in ACE2−/y mice. Concurrently, these mice exhibited an increase in hepatic
oxidative stress, evidenced by increased lipid peroxidation and expression of uncoupling protein 2, and downregulation of sirtuin
1. ACE2−/y mice also showed impairments in glucose metabolism and insulin signaling in the liver. Conclusions. Deletion of ACE2
causes CD36/sirtuin 1 axis impairment and thereby interferes with lipid homeostasis, leading to lipodystrophy and steatosis.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD), a metabolic dis-
order of increasing clinical importance with different patho-
logical presentations varying from initial hepatic steatosis,
through nonalcoholic steatohepatitis, to fibrosis and cirrho-
sis, has been considered a novel component of the metabolic
syndrome (MetS) [1, 2]. MetS is characterized by a cluster
of cardiovascular and metabolic disorders, including central
obesity, insulin resistance, glucose intolerance, dyslipidemia,
and hypertension [1, 2]. Emerging evidence indicates that
the renin-angiotensin system (RAS) plays an important
role in the pathogenesis of MetS and NAFLD [3–6]. The
“classical arm” (angiotensin converting enzyme/angiotensin
II/AT1 receptor [ACE/AngII/AT1]) promotes the disease [4–
6], whereas the “protective arm” (angiotensin converting
enzyme 2/angiotensin-(1–7)/Mas receptor [ACE2/Ang-(1–
7)/Mas]) counteracts it [3, 7, 8].
ACE acts on angiotensin I to form the AngII, a molecule
which constricts vessels after binding to the AT1 receptor
in arterioles [9, 10]. Beyond that, AngII has other func-
tions in the cardiovascular system that promote elevated
blood pressure, such as increased release of aldosterone and
vasopressin, which increase sodium and water reabsorption,
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respectively, in the renal distal tubules [11]. Therefore, ACE2
is an important enzyme that negatively regulates the RAS,
through reduction of AngII and increase of Ang-(1–7), a
vasodilator molecule, conferring ACE2 a protective role in
cardiovascular diseases [10, 11].
Metabolic studies demonstrated an important role of
the ACE2/Ang-(1–7)/Mas pathway in the maintenance of
homeostasis [3, 8, 12, 13]. Mice deficient for Mas presented
dyslipidemia and hyperglycemia [12]. Moreover, rats over-
expressing Ang-(1–7) showed an improvement in glucose
tolerance and insulin sensitivity and also exhibited decreased
triglycerides, cholesterol, and abdominal fat mass [8]. Treat-
ment of diabetic rats with an oral formulation of Ang-(1–7)
resulted in drastic reductions in glycemia and an increase in
insulin sensitivity, also implying insulin resistance under high
fat conditions [14]. Interestingly, ACE2 is not only a protease
which metabolizes peptides, such as AngII, apelin, and des-
Arg9-bradykinin [15], but is also involved in the resorption of
large amino acids from the gut [16, 17]. In this regard, ACE2
deletion leads to defects in amino acid uptake and intestinal
inflammation, but effects on lipid metabolism have not yet
been reported.
AngII has been shown to cause NAFLD [18], whereas
Ang-(1–7) elicits opposite effects [3]. Accordingly, both ACE
inhibitors and AT1 antagonists protect from fatty liver and
fibrosis [18], recombinant ACE2 has beneficial effects on
hepatic fibrosis in mice [19], and during the preparation
of this manuscript, Cao and collaborators [20] showed that
ACE2/Ang-(1–7)/Mas axis may reduce liver lipid accumula-
tion. On the other hand, the underlying mechanisms are not
yet well understood but, of the many factors that stimulate
this process, redox balance seems to be one of the most
important in the liver [21, 22].
Reactive oxygen species (ROS), such as nitric oxide (∙NO)
superoxide anion (∙O2
−) and hydrogen peroxide (H2O2), are
crucial mediators of angiotensin peptide actions [10], since
AngII promotes their generation [23] and Ang-(1–7) reduces
oxidative stress [10]. ROS are chronically elevated in NAFLD
and contribute to the pathogenesis of the disease [21, 22].
However, it is still unknown whether ACE2 plays a role
in this liver disorder or whether ACE2 deletion interferes
with regulation of key factors of lipid metabolism, such as
fatty acid translocase, also called cluster of differentiation
36 (CD36), peroxisome proliferator-activated receptor 𝛾
(PPAR𝛾), adipocyte protein 2 (aP2), fatty acid synthase (FAS),
and sirtuin 1, as well as of key moderators of ROS production
in hepatic metabolism, such as uncoupling protein type
2 (UCP2). Taking in consideration the important role of
angiotensins and ROS in the development of NAFLD [21,
22], we aimed to investigate the hepatic lipid profile in
ACE2-deficient mice in which the relative abundance of
AngII and Ang-(1–7) is distorted. Indeed, we found that the
deletion of ACE2 causes hepatic steatosis accompanied by an
impairment of the CD36/sirtuin 1 axis, insulin signaling, and
glucose metabolism in the liver. These results reveal a central
role of ACE2 in lipid homeostasis, preventing lipodystrophy
probably by decreasing the levels of AngII and/or increasing
Ang-(1–7) in the liver.
2. Methods
2.1. Animals and Experimental Procedures. C57BL/6 (WT)
and ACE2-deficient (ACE2−/y) male mice on C57BL/6
genetic background [9] at 3 and 6 months of age were used
in this study under standard diet (10% kcal from fat) from
SSNIFF (Soest, Germany). The mice were kept in a 12-
hour light/dark cycle, with controlled humidity and temper-
ature environment and fed ad libitum. All experiments were
approved by the “Landesamt fu¨r Gesundheit und Soziales”
(LAGeSo; Berlin) and performed in accordance with the
“Guide for the Care and Use of Laboratory Animals” (NIH
publication 86–23, 1996).
2.2. Euthanasia and Organ Collection. After intraperitoneal
(i.p) anesthesia using a xylazine/ketamine solution (10/110,
mg⋅kg−1), 12 h-fasted animals were euthanized by exsan-
guination through cardiac puncture of the right ventricle.The
whole blood was collected and centrifuged (4,000 rpm for
10min), and the plasma was separated and stored at −80∘C.
The animals were perfused with heparinized saline and, in
sequence, the liver and white adipose tissue (WAT) were
carefully removed, weighed, immediately frozen in dry ice
and stored at −80∘C until quantitative PCR, western blot
and the other analyses were performed. WAT index was
calculated using the following formula: WAT index (%) =
{(epididymal fat + perirenal fat)/(body weight)} ∗ 100.
2.3. Biochemical Analyses. Nonesterified fatty acid (NEFA)
kit was used to measure plasma and liver NEFA concen-
trations (Wako Chemicals GmbH, Neuss, Germany). The
total cholesterol (TCOL) and triglycerides (TG) levels were
assayed with commercials kits (Labtest, Belo Horizonte,
Brazil), following the manufacturers’ instructions with adap-
tations for microplates. All measurements were performed
with a TECAN Infinite 200 PRO plate reader (Ma¨nnedorf,
Switzerland).
2.4. Evaluation of Liver Injury. Liver injury (the degree of he-
patocellular damage) was assessed by measuring the enzy-
matic activities of alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) in plasma with commercial kits
(Labtest, Belo Horizonte, Brazil).
2.5. Liver and Fecal Lipids Analysis. The total hepatic and fe-
cal lipids were extracted according to a gravimetric standard
method [24]. Total lipids were measured by weighing the
samples on an analytical balance after extraction, being
normalized by the mass of faeces used for extraction. After
this, the total lipidswere diluted in isopropanol andmeasured
by commercial kits for TCOL, TG (Labtest, Belo Horizonte,
Brazil), and NEFA (Wako Chemicals GmbH, Neuss, Ger-
many).
2.6. Liver and WAT Histological Analysis. Fragments of liver
andWATwere fixed in 4%buffered formaldehyde, embedded
in paraffin and sectioned at 3 𝜇m and 10 𝜇m, respectively.
WAT was stained with H&E in order to determine adipocyte
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diameters. The lipid deposition in the liver was analyzed
indirectly by immunofluorescence staining for adipophilin.
In brief, sections were deparaffinized, rehydrated, and boiled
in citrate buffer, pH 7, for 20min in a vegetable steamer. The
sections were incubated with an antibody against adipophilin
(1 : 500, Fitzgerald, Acton, USA) overnight at 4∘C. The sec-
tions were then incubated with a secondary antibody conju-
gated with Cy3 (1 : 300) and coverslipped using the mounting
medium “Vectashild with DAPI-Hard set” (Vector Lab). The
sections were observed under a Keyence microscope (BZ
9000, Osaka, Japan). Digital photographs were taken from
each section; adipocyte diameter and adipophilin expression
were quantified using the “BZ II Analyzer” image processing
software (Keyence BZ 9000 Software, Osaka, Japan).
2.7. Lipid Peroxidation, Superoxide Dismutase, and Catalase
Activity Measurement in the Liver. The hepatic lipid per-
oxidation was quantified by measuring the ThioBarbituric
Acid-Reactive Substances (TBARS), a marker of oxidative
stress which was assayed by malondialdehyde (MDA) in liver
homogenates as described [25]. Total superoxide dismutase
(SOD) activity was assessed with a commercial colorimetric
kit (Sigma-Aldrich, Seelze, Germany). Catalase activity was
measured according to Xu et al. [26]. All results were
normalized to protein concentration [27].
2.8. Gluconeogenesis. Gluconeogenesis was evaluated by the
pyruvate test. It was performed after 16 hours overnight fast.
The animals were weighed and blood was collected from the
tail vein tomeasure glucose before the injection of 2 g sodium
pyruvate⋅kg−1 (i.p) (Sodium Pyruvate, Sigma-Aldrich, Seelze,
Germany). After injection, the glucose levels were measured
at 15, 30, 60, 90, and 120 minutes.
2.9. Real Time Quantitative PCR. Total RNA was isolated
from liver using Trizol (TRizol Reagent, Invitrogen, Darm-
stadt, Germany) and subsequently cleaned using RNeasy
Mini kit (Qiagen, Hilden, Germany). RNA concentrationwas
quantified using spectrophotometry (NanoDrop, Mu¨nchen,
Germany) and 1 𝜇gwas taken for the synthesis of cDNAusing
M-MLV Reverse Transcriptase (Invitrogen). The reaction
product was amplified using the GoTaq qPCR Master Mix
(Promega; Mannheim, Germany) by real time quantitative
PCR (ABI 7900HT Real-Time PCR System-Applied Biosys-
tems, Darmstadt, Germany) with gene-specific primers (se-
quences listed in Table 1; Supplemental Data in Supplemen-
tary Material available online at http://dx.doi.org/10.1155/
2016/6487509).ThemRNAexpression level was quantified by
normalization to the internal reference, GAPDH, using the
2−ΔΔCt method [28].
2.10. Western Blotting. For Western blotting, proteins were
isolated using a lysis buffer (Cell Signaling Technology,
Beverly, MA) containing mammalian protease and phos-
phatase inhibitor cocktail (Roche, Mannheim, Germany)
and quantified by Bradford assay [27]. The proteins were
separated by electrophoresis, transferred to a polyvinylidene
fluoride membrane, which was blocked by incubation in
Odyssey blocking buffer (Li-COR, Biosciences, Lincoln,
USA) for 1 h at room temperature (RT).Thereafter, the mem-
brane was probed (overnight, 4∘C) with one of the following
primary antibodies: UCP2 (1 : 500), sirtuin 1 (1 : 1,000),𝛼-IRS-
1 (1 : 1,000), PI3-K (1 : 500), AKT (1 : 1,000), phospho-GSK 3𝛽
(1 : 1,000), and GSK 3𝛽 (1 : 1,000) followed by incubation with
a secondary antibody for 1 h at RT. Band intensities were
acquired and quantified using the Odyssey infrared imaging
system (Li-COR, Biosciences, Lincoln, USA).Themembrane
was stripped and reprobed with 𝛽-actin (1 : 1,000) antibody to
obtain an endogenous control for protein quantification.
2.11. Statistical Analysis. Data are expressed as mean ± stan-
dard error of the mean (SEM). Student’s t-test was performed
for the between-group comparisons (Graph Pad Prism 5.0,
San Diego, CA, USA). The hepatic gluconeogenesis test was
analyzed by two-way ANOVA followed by Bonferroni’s post-
test. 𝑝 < 0.05 was considered statistically significant.
3. Results
3.1. ACE2 Deficiency Decreases Body Weight and Changes
the Plasma Lipid Profile. To reveal the role of ACE2 in fat
metabolism, we evaluated body (BW) and white adipose
tissue (WAT) weight and plasma lipid profile in ACE2−/y
mice. These animals showed lower BW and WAT index at 3
and 6 months of age compared toWTmice (Figures 1(a) and
1(b)) and a decrease inwhite adipocyte diameter (Figure 1(c)).
The reduction in these parameters was accompanied by
decreased lipids in plasma. In 3- and 6 month-old mice, the
levels of NEFA in plasma were significantly lower, and at 6
months of age also TCOL and TG were reduced in ACE2−/y
mice compared to WT animals (Figures 1(d)–1(f)).
3.2. ACE2 Deficiency Leads to Hepatic Steatosis and Oxidative
Stress. As ACE2
−/y
mice develop intestinal dysfunction [16,
17], we investigated whether the missing plasma lipids were
released to the faeces in 6-month-old mice. The results
showed that there were no significant differences in total
lipids, TCOL, TG, and NEFA levels between WT and
ACE2−/y mice (Figures 1(g)–1(j)). However, when we investi-
gated ectopic fat deposition, we identified lipid accumulation
in the liver. Immunofluorescence staining for adipophilin, a
lipid droplet-associated protein, showed a higher fat deposi-
tion in ACE2−/y mice at 6 months of age compared to WT
(Figures 2(a) and 2(b)). These data indicate that ACE2−/y
mice present a steatotic state.
Although these animals showed no difference in relative
liver weight (Figure 2(c)), they stored increased levels of
TCOL, TG, and NEFA in the liver at the age of 3 months and
of TG and NEFA at the age of 6 months compared to WT
(Figures 2(d)–2(f)). Plasma ALT was significantly increased
in ACE2−/y mice at both ages (Figure 2(g)), and plasma
ASTwas also significantly increased in 6-month-oldACE2−/y
mice (Figure 2(h)), confirming liver injury in these animals.
Expression analysis of genes, involved in lipidmetabolism
in the liver, showed that ACE2−/y mice have significantly
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Figure 1: Body weight, WAT index and lipid profile in ACE2−/y mice. (a) Body weight (g); (b) WAT index (%) of WT and ACE2−/y mice at
the age of 3 and 6 months; (c) white adipocyte diameter (𝜇m); (d) total cholesterol (mg⋅dL−1), (e) triglycerides, (mg⋅dL−1), (f) nonesterified
fatty acids (NEFA) (mmol⋅L−1) in plasma of WT and ACE2
−/y
mice at the age of 3 and 6 months; (g) total lipids (g⋅g−1 of faeces), (h) total
cholesterol (mg⋅g−1 of faeces), (i) triglycerides (mg⋅g of faeces−1), and (j) NEFA (mmol⋅g of faeces−1) in faeces of WT and ACE2−/y mice at
the age of 6 months. Each bar graph represents the mean ± SEM. Student’s t test: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
more mRNA for CD36, but the levels of mRNA for PPAR𝛾,
aP2, and FAS in the liver were not different between ACE2−/y
and WT mice (Figure 3).
ACE2−/y mice showed increased hepatic lipid peroxi-
dation at the age of 3, but not 6 months (Figure 4(a)).
Next, we analyzed antioxidant enzymes in liver homogenates.
SOD activity showed no difference between ACE2−/y and
WT at the age of 6 months. However, catalase activity
was significantly higher in ACE2−/y mice compared to WT
(Figures 4(b) and 4(c)). In addition, the expression of the
UCP2 was significantly higher in ACE2−/y mice compared to
WT at mRNA (Figure 4(d)) and protein levels at both ages
(Figure 4(e)), suggesting that the steatosis is accompanied
by oxidative stress. The levels of sirtuin 1 were significantly
decreased in liver of 6- but not 3-month-old ACE2−/y mice
compared to WT (Figure 4(f)).
3.3. ACE2 Deficiency Leads to Impaired Insulin Signaling in
the Liver. As steatosis is often associated with insulin resis-
tance [2], we investigated glucose metabolism and insulin
signaling in the liver of ACE2−/y mice. In this organ, ACE2−/y
mice showed severe impairment in insulin signaling and
Oxidative Medicine and Cellular Longevity 5
WT 6 monWT 3 mon
Adipophilin
DAPI
ACE2−/y 3 mon ACE2−/y 6 mon
(a)
0
4
8
12
16
Ad
ip
op
hi
lin
(%
 ar
ea
/v
ie
w
 fi
el
d)
∗
3 mon 6 mon
WT
ACE2−/y
(b)
0.0
1.2
2.4
3.6
4.8
6.0
Re
lat
iv
e l
iv
er
 w
ei
gh
t (
%
)
3 mon 6 mon
WT
ACE2−/y
(c)
To
ta
l c
ho
le
ste
ro
l i
n 
liv
er
∗∗
3 mon 6 mon
WT
ACE2−/y
0
2
4
6
8
10
(m
g·
g−
1
of
 li
ve
r)
(d)
Tr
ig
ly
ce
rid
es
 in
 li
ve
r
∗
∗∗
3 mon 6 mon
WT
ACE2−/y
0.0
2.4
4.8
7.2
9.6
12.0
(m
g·
g−
1
of
 li
ve
r)
(e)
N
EF
A
 in
 li
ve
r
∗
∗∗∗
3 mon 6 mon
WT
ACE2−/y
0.000
0.012
0.024
0.036
0.048
0.060
(m
m
ol
·g
−
1
of
 li
ve
r)
(f)
0.0
2.4
4.8
7.2
9.6
12.0
∗∗
∗∗∗
3 mon 6 mon
A
LT
 in
 p
la
sm
a (
U
·L
−
1
)
WT
ACE2−/y
(g)
0
5
10
15
20
∗∗
3 mon 6 mon
A
ST
 in
 p
la
sm
a (
U
·L
−
1
)
WT
ACE2−/y
(h)
Figure 2: Hepatic steatosis and liver function of ACE2−/y mice. (a) Immunofluorescence staining for adipophilin in the liver; (b) adipophilin
quantification (% area/view field); (c) relative liver weight (%); (d) total cholesterol in liver (mg⋅g−1 of liver); (e) triglycerides in liver (mg⋅g−1
of liver); (f) nonesterified fatty acids (NEFA) in liver (mmol⋅g−1 of liver); (g) alanine aminotransferase (ALT) in plasma (U⋅L−1); (h) aspartate
aminotransferase (AST) in plasma (U⋅L−1) of WT and ACE2−/y mice at the age of 3 and 6 months. Each bar graph represents the mean ±
SEM. Student’s t test: ∗𝑝 < 0.05;∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
glucose handling. Whereas the hepatic capacity of glucose
production from pyruvate was not altered in these mice
(Figure 5(a)), several genes involved in glucose metabolism
were dysregulated. ACE2−/y mice presented a reduction
in the relative expression of glucokinase (GCK) and of
glucose transporter type 2 (GLUT2) and increased levels of
expression of glucose 6-phosphatase (G6Pase) and phospho-
enolpyruvate carboxykinase subtype 2 (PCK2). The other
subtype, PCK1, and the insulin receptor were however not
differentially expressed between the groups (Figure 5(b)).
Moreover, ACE2−/y mice presented a significant decrease
in proteins involved in glycolysis, such as insulin receptor
substrate-1 (𝛼IRS-1), phosphatidyl inositol-3 kinase (PI3-K),
and AKT compared to WT (Figures 5(c)–5(e)). Further-
more, GSK 3𝛽 and phosphorylated GSK 3𝛽 were decreased
in ACE2−/y mice (Figures 5(f) and 5(g)). However, GSK
3𝛽/phosphorylated GSK 3𝛽 ratio was not different between
groups (Figure 5(h)).
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Figure 5: Hepatic glucose metabolism. (a) Evaluation of hepatic gluconeogenesis stimulated by intraperitoneal injection of pyruvate and area
under the curve of the test (AUC); (b) relative mRNA expression of glycolytic genes in the liver (glucokinase, GCK; glucose 6-phosphatase,
G6Pase; phosphoenolpyruvate carboxykinase 1 and 2, PCK; insulin receptor, IR; and glucose transporter type 2, GLUT2) (arbitrary units);
(c) 𝛼-insulin receptor substrate-1 (𝛼IRS) protein expression in the liver (arbitrary units); (d) phosphatidyl inositol-3 kinase (PI3-K) protein
expression in the liver (arbitrary units); (e) AKT protein expression in the liver (arbitrary units); (f) glycogen synthase kinase (GSK) 3𝛽 in
the liver (arbitrary units); (g) phospho-GSK 3𝛽 in the liver (arbitrary units); (h) GSK 3𝛽/phospho-GSK 3𝛽 in the liver (arbitrary units) ofWT
and ACE2−/y mice at the age of 6 months. Data are presented as mean ± SEM. Student’s 𝑡 test: ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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4. Discussion
The major findings of the present study are that the deletion
of ACE2 causes paradoxical metabolic effects: on the one
hand, it results in a markedly diminished BW and WAT.
On the other hand, it leads to the development of steatosis
and insulin resistance in the liver. Evidence for this disorder
includes an increased amount of adipophilin-containing vesi-
cles in hepatocytes (Figures 2(a) and 2(b)), augmented lipids
in the liver (Figures 2(d)–2(f)), and an accumulation of liver
enzymes in plasma as indication of liver injury (Figures 2(g)
and 2(h)). The decrease of WAT index, adipocyte diameter
(Figures 1(b) and 1(c)), and plasma lipids (Figures 1(d)–1(f))
associated with the normal faecal lipid excretion (Figures
1(g)–1(j)) suggested an increased uptake of fatty acids by
the liver as primary cause for the NAFLD observed in
ACE2−/y mice. Indeed, CD36, the fatty acid translocase, is
upregulated in mice lacking ACE2 (Figure 3). It has been
shown that the upregulation of CD36 in the liver is associated
with increased steatosis in NAFLD patients [29, 30] and
CD36−/−mice are resistant to alcohol and high carbohydrate-
induced hepatic steatosis [31]. Moreover, inmice and humans
aging increases CD36 membrane expression in the liver [29],
causing increased fat uptake and advancing NAFLD with
age. The increase in CD36 may be caused by the decreased
expression of sirtuin 1 in ACE2−/y mice (Figure 4(f)), as
it was observed in heterozygous sirtuin 1 deficient animals
[32]. In addition, Cao and collaborators [33] showed that
the deletion of hepatocyte-specific menin causes steatosis
in aging mice by decreasing the levels of sirtuin 1 in the
liver and upregulation of CD36, which demonstrates a
metabolic link between CD36 and sirtuin 1. AngII has been
shown to downregulate sirtuin 1 in other cell types [34] and
Ang-(1–7) exhibit the opposite effect in liver cells [35]. Thus,
a downregulation of this translocase can be expected from
the imbalance between the two peptides in ACE2−/y mice.
Interestingly, it has recently been shown that sirtuin 1 can vice
versa regulate ACE2 expression [36].
Increase in cytosolic fatty acids leads to mitochondrial
damage and the production of reactive oxygen species (ROS)
[21]. Moreover, hepatic sirtuin 1 deficiency in mice induces
oxidative liver damage [37]. Indeed, we observed increased
lipid peroxidation andUCP2 expression as oxidative markers
also in the liver of ACE2−/y mice suggesting that steatosis is
accompanied by elevated oxidative stress in these animals.
The high lipid peroxidation observed in the ACE2−/y mice
at the age of 3 months is probably due to a high production
of H2O2 in these mice [38]. This could explain the high
catalase activity, which degrades H2O2, in an attempt to
combat the elevation of this ROS [38]. UCP2, amitochondrial
anion carrier protein [39], plays a key role as a moderator of
ROS production in hepatic metabolism [40, 41]. Accordingly,
UCP2−/− mice showed increased ROS formation [42]. In
ACE2−/y mice, an increase in intracellular lipids in the liver
may lead to amitochondria overload, followed by an increase
in ROS production during the 𝛽-oxidation of lipids, which
in turn stimulates the expression of UCP2 to combat this
imbalance. These data suggest that the increased expression
of this uncoupling protein could be an insufficient defense
mechanism in the attempt to prevent the progression of
steatosis in ACE2−/y mice [43]. We cannot exclude that
AngII-induced oxidative stress may be a primary cause of
liver steatosis in ACE2−/y mice, which is not compensated by
Ang-(1–7) in these animals. Experimental evidence indicates
that RAS signaling plays a critical role in the metabolism
of fat in the liver [3, 4, 7, 18, 19, 44]. Moreover, Cao and
collaborators [20] recently confirmed that ACE2−/y mice
present hepatic steatosis, oxidative stress, and inflammation.
This report also showed that Ang-(1–7) and ACE2 amelio-
rated all of these parameters in a liver cell line. The authors
attribute the reduction of liver lipid accumulation, induced by
ACE2/Ang-(1–7)/Mas axis, partly to the regulation of lipid-
metabolizing genes.
As already described in other mouse models and patients
[45], the high lipid deposition in the liver of ACE2−/y mice
resulted in impaired insulin signaling and glucose metab-
olism. Although these animals showed normal glucose pro-
duction from pyruvate, changes in the expression of impor-
tant genes for glucose metabolism, such as GCK, G6Pase,
PCK2, and GLUT2, suggest that as a result of steatosis,
glycolysis could be impaired. Furthermore, the decrease in
IRS-1, PI3-K, AKT, andGSK3𝛽 pathway confirms that insulin
signaling is impaired in the liver of ACE2−/y mice. Accord-
ingly, Cao and collaborators [46] showed that the activation
of the ACE2/Ang-(1–7)/Mas axis has a beneficial effect on
insulin resistance in the liver through reduced oxidative stress
in hepatic cells and modulation of the Akt/PI3K/IRS-1/JNK
insulin signaling pathway.
ACE-deficient mice show a pronounced increase in
expression of key genes involved in lipolysis and fatty acid
oxidation in the liver, such as lipoprotein lipase, carnitine
palmitoyl transferase, and long-chain acetyl CoA dehydroge-
nase. This suggests an increase in fatty acid hydrolysis and 𝛽-
oxidation, which could prevent an accumulation of lipids in
the liver and might be due to the absence of AngII in these
knockout animals [6]. On the other hand, ACE2-deficient
mice have increased levels of AngII which is known to con-
tribute to the development of steatosis and insulin resistance
[45]. AT1 receptor activation leads to steatosis via decreased
UCP2 in a rat model with metabolic syndrome [47], and
the deletion of AT1 receptor reduces hepatic steatosis [44].
Moreover, it has been shown that the oral treatment with
Ang-(1–7) prevents HFD-induced steatosis [7] and that the
deletion of Mas in ApoE-deficient mice leads to an increased
hepatic lipid content [3]. Taken together, this large body of
experimental evidence and our results show that a balanced
activity of the two axes of the RAS, ACE/AngII/AT1 and
ACE2/Ang-(1–7)/Mas, is essential tometabolize fat for energy
maintenance in the liver without inducing steatosis. The
observed BW reduction in ACE2-deficient mice confirms the
findings of Singer et al. [17], who link it to the defective amino
acid absorption in the gut of these animals. However, the
reduction in WAT by the mechanism described in our study
may also contribute to this phenotype. Future studies have to
validate the proposedmechanisms bywhich angiotensin pep-
tides regulate lipid metabolism and hepatic oxidative stress.
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Figure 6: Proposed mechanism of hepatic steatosis in ACE2−/y mice. ACE2 deletion causes an imbalance between Ang-(1–7) and AngII with
higher levels of the latter. Since Ang-(1–7) via Mas stimulates and AngII via the AT1 receptor inhibits sirtuin 1 expression, this regulatory
factor is downregulated. This leads to upregulation of the fatty acid translocase, CD36, and an increased uptake of nonesterified fatty acids
(NEFA) into hepatocytes causing ectopic fat deposition and oxidative stress in the liver. Oxidative stress is augmented by direct effects of the
decreased sirtuin 1 and the increased AT1-signalling on the formation of reactive oxygen species. In the blood, NEFAs are decreased leading
to shrinking adipocytes and fat pads, as well as a drop in body weight.
In sum, ACE2 deletion causes CD36/sirtuin 1 axis impair-
ment and thereby contributes to the fat deposition in the
liver leading to NAFLD, oxidative stress, and impaired
insulin signaling (summarized in Figure 6).Therefore, ACE2-
deficient mice provide a suitable model for assessing the
pathophysiological relevance of NAFLD and represent an
excellent tool to investigate new therapeutic strategies for
MetS as well as associating disorders.
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